Given that efforts to develop pharmacological inhibitors of glucagon receptor signaling as a therapy for hyperglycemia in T2DM continue (26, 27, 40), it is critical to understand the potential consequences of blocking glucagon receptor signaling at the adipocyte. The gene discussed is GCGR; the disease is type 2 diabetes mellitus.